NCT05202977Enrolling By InvitationNot Applicable
A Prospective，Multicenter, Single-arm Clinical Trial to Evaluate Safety and Efficacy of SinocrownTM Transcatheter Aortic Valve Replacement System With Accessories in Patients With Symptomatic, Calcified and Severe Aortic Stenosis
Lepu Medical Technology (Beijing) Co., Ltd.1 site in 1 country10 target enrollmentStarted: April 6, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- device success
Study Overview
Brief Summary
This study was designed to preliminary verify the safety and of efficacy of SinocrownTM Transcatheter Aortic Valve Replacement System With accessories in patients with symptomatic, calcified and severe aortic stenosis using objective performance criteria
Detailed Description
This prospective, single-center, single-arm clinical trial was designed to preliminary confirm the safety and efficacy of SinocrownTM transcatheter aortic valve system with accessories.
According to the inclusion and exclusion criteria, 10 patients were enrolled and implanted with SinocrownTM .Patients will been followed up 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after valve implantation. The main follow-up included clinical symptoms and signs, cardiac ultrasound, etc. The primary endpoint was device success after TAVR, Secondary endpoints included procedural success, all-cause mortality, myocardial infarction, disabling stroke, severe bleeding, acute kidney injury, permanent pacemaker implantation, vascular complications, other complication, MACCEs, valvular function , cardiac function improvement, quality of life of patients.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to — (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 65 years ;
- •Autologous degenerative aortic stenosis（evaluated by echocardiography: transaortic valve pressure gradient ≥40mmHg , or transaortic valve blood flow rate ≥4m/s, or aortic Valve area<1.0cm2, or AVA <0.5cm2 /m2）
- •Patients with aortic annulus size≥17.5mm and ≤29mm (echocardiography measurement);
- •The diameter of the ascending aorta of the patient was < 45mm.
- •Appear obvious symptoms caused by aortic stenosis, NYHA class Ⅱ to IV;
- •Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
- •Subjects are willing to accept all clinical follow-up.
- •The cardiologist and cardiac surgeon evaluated the subject as unsuitable for surgical treatment (the risk of death or irreversible complications within 30 days after operation is expected to be above 50% , or contraindicated comorbidities such as prior chest radiotherapy, liver failure, diffuse severe calcification of the aorta, extreme weakness, etc.). Or Moderate or higher surgical risk (STS score ≥ 4%).
Exclusion Criteria
- •defined as Q-wave myocardial infarction or non-Q-wave myocardial infarction with CK-MB level ≥ 2 times the upper limit of normal value and / or Tn increase.
- •Subjects with congenital unicuspid, without calcification.
- •Any therapeutic or traumatic cardiac surgery within 30 days (within 3 months in case of drug-eluting stents implantation)
- •The patient's heart has been implanted with other artificial heart valves, artificial rings, or severe mitral annulus calcification (MAC), severe (> 3 +) mitral insufficiency.
- •Hematological abnormalities, including leukopenia (WBC<3×109/L), acute anemia (HB <90g/L), thrombocytopenia (PLT<50×109/L), bleeding constitution and coagulopathy ；
- •Subjects with hemodynamic instability, requiring continuous mechanical heart assistance.
- •Subjects who need emergency surgery for any reason;
- •Hypertrophic cardiomyopathy with or without obstruction;
- •Severe left ventricular dysfunction, left ventricular ejection fraction (LVEF) <20%;
- •The echocardiogram indicates the presence of a thrombus or vegetation;
- •A history of active peptic ulcer or upper gastrointestinal bleeding within 3 months;
- •Are allergic to nickel titanium alloys or contrast agents, and cannot tolerate anticoagulation and antiplatelet therapy;
- •Cerebrovascular accident occurred within 6 months, including transient ischemic attack;
- •renal insufficiency(creatinine> 3.0mg/dL) and/or end-stage renal disease requiring Renal dialysis;
- •Life expectancy< 12 months;
- •Significant aortic diseases, including abdominal aortic or thoracic aortic aneurysm(defined as maximum lumen diameter > 50mm, obvious distortion), atherosclerosis of the aortic arch(especially bulge with thickness > 5mm or ulceration), narrowing of the abdominal or thoracic aorta(especially calcification and irregular surface), and severe curvature of the thoracic aorta;
- •The iliac-femoral artery cannot be inserted with a guide sheath of 22F or above, such as severely obstructed with calcification, severely tortuous or vessel diameter less than 6mm;
- •Screening participant who is participating in other drug or medical device clinical trials;
- •Active infective endocarditis or other active infections;
- •Anatomically, the approach or aortic root is not suitable for TAVR (such as a high risk of coronary artery occlusion).
- •Other conditions considered by the investigator to be inappropriate for participation in this clinical trial.
Outcomes
Primary Outcomes
device success
Time Frame: immediate post-surgical
Immediate postoperative device success was defined as : successfully loading the valve into the delivery system, sending it to the target site through the delivery system, accurately releasing the artificial aortic valve and completely withdrawing the delivery system (valve orifice area \> 1.2cm2, mean aortic gradient\< 20mmhg or maximal aortic valve velocity \< 3 m/ s, and there is no moderate or severe valve stenosis)
Secondary Outcomes
- Procedural success(immediate post-surgical)
- All-cause mortality(immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- Myocardial infarction(immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- Rate of disabling stroke(7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- Rate of Severe bleeding(life-threatening or disabling)(7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- acute kidney injury(7 days after procedure/prior to discharge, 30 days after procedure)
- permanent pacemaker implantation(7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- vascular complications(immediate post-surgical, 7 days after procedure/prior to discharge)
- other operative complication(immediate post-surgical, 7 days after procedure/prior to discharge)
- The incidence of major adverse cardiovascular and cerebrovascular events during the trial(MACCEs)(immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- Valve and heart function(immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months)
- Cardiac function improvement(7 days after procedure/prior to discharge, 30 days, 6 months, 12 months)
- Quality of life of patients(30 days, 6 months, 12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCCLenvatinibHepatocellular CarcinomaNCT04911959Second Affiliated Hospital, School of Medicine, Zhejiang University50
Completed
Not Applicable
PREVAIL-J - Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Japan)Aortic Valve StenosisNCT01113983Edwards Lifesciences64
Recruiting
Not Applicable
Medical device approval of oligomerized amyloid-ß measurement technologyDiseases of the nervous systemKCT0002581PeopleBio104
Recruiting
Not Applicable
PARTNER 3 Trial - Aortic Valve-in-ValveAortic Stenosis, SevereAortic StenosisNCT03003299Edwards Lifesciences125
Not yet recruiting
Not Applicable
Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty SystemTricuspid RegurgitationNCT05173233Shanghai Huihe Medical Technology Co., Ltd67